Date: August 3, 2026

KMP / Board / Auditor Changes

Not Specified

Dividend Declaration or Non-Declaration

Not Specified

Board Meeting Outcomes

Not Specified

Financial Results (Standalone & Consolidated)

Not Specified

Disinvestment / Strategic Actions

Not Specified

Other Operational / Legal / Strategic Disclosures

General Company Information

  • Corporate Identity Number (CIN): L73100MH1999PLC119744
  • Year of Incorporation: 1999
  • Financial Year Reported: 2025-26
  • Stock Exchanges: BSE Limited & National Stock Exchange of India Limited
  • Paid-up Capital: ₹16,50,92,124
  • BRSR Contact: Ms. Deepashree Tanksale, Company Secretary, Telephone: +91 022 65435800, Email: secretarial@rubicon.co.in
  • Reporting Boundary: Standalone
  • Assurance Provider: Not Applicable

Products/Services

  • Business Activity: Pharmaceutical formulations (100% of turnover)
  • NIC Code: 21002
  • Description: Innovation-driven development, manufacturing and marketing of branded specialty and generic pharmaceutical products

Operations

  • Number of Locations: National - 5 (3 plants, 2 offices), International - 7 offices
  • Markets Served: National - 3 states, International - 8 countries
  • Export Contribution: 98.44% of total turnover
  • Customer Types: Wholesalers, major pharmacy chains, group purchasing organizations (GPOs), regional and national pharmacy networks, Managed Care Organizations
  • Primary Markets: United States through subsidiaries Validus and AdvaGen Pharma and third-party sales entities

Employees

  • Total Employees: 1,303 (Permanent: 1,290, Other than Permanent: 13)
  • Male: 1,080 (82.89%), Female: 223 (17.11%)
  • Total Workers: 582 (All Other than Permanent)
  • Male: 558 (95.88%), Female: 24 (4.12%)
  • Differently Abled: 0 employees and 0 workers
  • Women Representation: Board of Directors - 2 out of 8 (25%), Key Management Personnel - 1 out of 2 (50%)
  • Turnover Rate (Permanent Employees): FY 2025-26 - Male: 19.27%, Female: 21.95%, Total: 19.74%

Subsidiary Companies

1. Advagen Holdings Inc (100% subsidiary)

2. AdvaGen Pharma Limited (100% subsidiary)

3. AIM RX3PL LLC* (100% subsidiary)

4. Validus Pharmaceuticals LLC* (100% subsidiary)

5. Kinaxon Bio Inc (100% subsidiary)

6. Advagen Pharma Europe OÜ (100% subsidiary)

7. Rubicon Research Australia Pty Ltd (100% subsidiary)

8. KIA Health Tech Private Limited (100% subsidiary)

9. Rubicon Consumer Healthcare Private Limited (100% subsidiary)

10. Rubicon Academy LLP* (98.04% subsidiary)

11. Rubicon Research Canada Limited (100% subsidiary)

12. Rubicon Research Private Limited (Singapore) (100% subsidiary)

13. AdvaGen S A Company (subsidiary by control)

*Investment considered as equity contribution

CSR Details

  • CSR Applicable: Yes as per Section 135 of Companies Act, 2013
  • Turnover: ₹13,060.82 Million
  • Net Worth: ₹13,209.83 Million

Complaints/Grievances

  • Shareholders: 18 complaints filed during year, 0 pending resolution
  • All other stakeholder groups (Communities, Investors, Employees, Workers, Customers, Value Chain Partners): Nil complaints received
  • Customer complaint mechanism: SOP for handling customer complaints, adverse drug experiences; Email: pv@rubicon.co.in / pv@advagenpharma.com; Toll free: +1 (866) 488-0312

Material Responsibility & Sustainability Issues

1. Corporate Governance & Business Ethics (Risk & Opportunity)
  • Risk: Regulatory non-compliance, legal/financial liabilities, reputational damage
  • Opportunity: Strengthen regulatory compliance, enhance stakeholder trust
  • Approach: Robust governance structures, periodic audits, compliance monitoring
  • Financial Implications: Negative - penalties, liabilities; Positive - risk mitigation, value creation
2. Innovation & Research (Opportunity)
  • Rationale: Fundamental to business, drives product development and competitiveness
  • Financial Implications: Positive - revenue growth, market competitiveness
3. Human Capital Development (Opportunity)
  • Rationale: Enhances operational efficiency, product quality, innovation
  • Financial Implications: Positive - productivity, revenue growth, profitability
4. Product Quality & Safety (Risk & Opportunity)
  • Risk: Regulatory actions, product recalls, legal liabilities
  • Opportunity: Customer trust, regulatory compliance
  • Approach: Stringent quality assurance, quality control, pharmacovigilance
  • Financial Implications: Positive - customer confidence; Negative - recalls, penalties
5. Cybersecurity & Data Privacy (Risk & Opportunity)
  • Risk: Information compromise, business disruption, regulatory consequences
  • Opportunity: Operational resilience, stakeholder trust
  • Approach: Information security framework, security controls, employee training
  • Financial Implications: Negative - penalties, disruptions; Positive - risk reduction
6. Supply Chain Management (Risk & Opportunity)
  • Risk: Operational delays, increased costs
  • Opportunity: Operational efficiency, cost effectiveness
  • Approach: Business continuity plans, risk management, supply chain diversification
  • Financial Implications: Negative - increased costs; Positive - cost optimization
7. Waste Management (Risk)
  • Rationale: Environmental risks if not managed properly
  • Approach: Sustainable waste management system, hazardous waste sent for pre-processing/co-processing through authorized agencies
  • Financial Implications: Negative - legal actions, reputational damage
8. Energy Efficiency & Climate Change (Opportunity)
  • Rationale: Reduces energy consumption, pollution, GHG emissions
  • Financial Implications: Positive - cost saving, emission minimization
9. Occupational Health & Safety (Risk)
  • Rationale: Safety incidents causing distress and reputational loss
  • Approach: Regular training, risk assessment, corrective action plans
  • Financial Implications: Negative - performance impact, talent retention issues
10. Enhancing Accessibility of Medicines (Opportunity)
  • Rationale: Expands customer base, enhances market perception
  • Financial Implications: Positive - business expansion, revenue generation

Management and Process Disclosures

  • Policies cover all 9 NGRBC Principles, approved by Board
  • Policies available at: www.rubicon.co.in/investors and company intranet
  • Policies extend to value chain partners: In process of developing supplier policies
  • National/International Standards: Drugs and Cosmetics Rules 1945, Good Clinical Practice Guidelines, CDSCO guidelines, Narcotic Drugs and Psychotropic Substances Act 1985

Specific Commitments and Targets

  • Principle 3: Maintain Lost Time Injury (LTI) rate at 0%
  • Principle 6:
  • Increase renewable energy use by 30% through solar system and group captive power by 2030
  • Enhance green cover and biodiversity through tree plantation at manufacturing plants
  • Achieve water neutrality by 2030 through water table increase
  • Ensure 100% disposal of hazardous waste through authorized facilities by 2030

Governance and Leadership

  • Director Statement: ESG integrated into decision-making, governance structures, and operations
  • Highest Authority: Mr. Parag Sancheti, Executive Director & CEO
  • Board Committee: Audit Committee and Risk Management Committee oversee sustainability matters
  • Policy Review: Periodic review by Directors/Board Committees/Functional Heads
  • Compliance Review: Quarterly review by Board and Audit Committee

Principle-wise Detailed Disclosures

Principle 1: Ethical, Transparent and Accountable Business
  • Training Coverage: Board - 100%, KMP - 100%, Employees - 94%, Workers - 100%
  • Fines/Penalties: Nil
  • Anti-corruption Policy: Yes, available at www.rubicon.co.in/investors
  • Disciplinary Actions: Nil against Directors/KMPs/employees/workers
  • Conflict of Interest Complaints: Nil
  • Accounts Payable Days: FY 2025-26 - 88.94 days, FY 2024-25 - 68.57 days
  • Related Party Transactions: Purchases - 0.36%, Sales - 78.87%, Loans & Advances - 100%, Investments - 82.18%
Principle 2: Sustainable and Safe Goods/Services
  • R&D Investment in ESG: FY 2025-26 - 0%, FY 2024-25 - 1.56%
  • Capex Investment in ESG: FY 2025-26 - 1.30% (INR 21.12 Million in solar power)
  • Sustainable Sourcing: Procedures in process of being set up
  • Waste Reclamation Processes: Detailed processes for plastics, e-waste, hazardous waste, other waste
  • Extended Producer Responsibility: Registered as importer, proposal secured from CPCB
  • Waste Quantities (MT):
  • Plastics: Recycled - 37.90 (FY25-26), 26.45 (FY24-25)
  • E-waste: Recycled - 0 (FY25-26), 0.218 (FY24-25)
  • Hazardous: Recycled - 67.17, Safely disposed - 13.81 (FY25-26); Recycled - 6.314, Safely disposed - 88.16 (FY24-25)
  • Other: Recycled - 214.12 (FY25-26), 124.35 (FY24-25)
Principle 3: Employee Well-being
  • Employee Well-being Measures:
  • Permanent Employees: Health insurance - 100%, Accident insurance - 100%, Maternity benefits - 100% (female), Paternity benefits - 100% (male), Day care - 100%
  • Workers: No benefits coverage
  • Well-being Spending: 0.19% of total revenue (FY25-26), 0.25% (FY24-25)
  • Retirement Benefits:
  • PF: Employees - 99.69% coverage, Workers - 100% coverage, Deposited - Yes
  • Gratuity: 100% coverage for both, Deposited - Yes
  • ESI: Employees - 10.16% coverage, Workers - 100% coverage, Deposited - Yes
  • Workplace Accessibility: Assessment underway for differently abled accessibility
  • Parental Leave Return: Male - 100%, Female - 83.33%, Total - 1.67%
  • Training:
  • Employees: Health & safety - 23.02% coverage, Skill upgradation - 36.05% coverage
  • Workers: Health & safety - 64.78% coverage, Skill upgradation - 0%
  • Performance Reviews: Employees - 82.40% coverage
  • Safety Incidents: All categories - 0 for both employees and workers
Principle 4: Stakeholder Responsiveness
  • Stakeholder Identification: Comprehensive process mapping stakeholders across value chain
  • Engagement Channels: Multiple channels including emails, portals, meetings, events
  • Engagement Frequency: Frequent and need-based for all stakeholder groups
  • Vulnerable Groups: Local community beneficiaries of CSR activities considered vulnerable/marginalized
Principle 5: Human Rights
  • Human Rights Training: Employees - 96.16% coverage, Workers - 0% coverage
  • Minimum Wages: 100% compliance for all employees and workers
  • Median Remuneration:
  • Board: Male - ₹25,00,000, Female - ₹88,10,000
  • KMP: Male - ₹3,01,40,000, Female - ₹15,90,000
  • Employees: Male - ₹6,61,400, Female - ₹6,31,200
  • Gross Wages to Females: 19.81% of total wages (FY25-26), 21.35% (FY24-25)
  • Human Rights Focal Point: Yes, HR and Compliance functional heads
  • Complaints: All human rights categories - 0 complaints
  • POSH Complaints: 0 reported, 0 upheld
  • Human Rights in Contracts: Yes, incorporated into business agreements
  • Assessments: 100% assessment coverage for all human rights categories
Principle 6: Environmental Protection
  • Energy Consumption:
  • Renewable: 1,400.21 GJ (FY25-26), 1,660.64 GJ (FY24-25)
  • Non-renewable: 104,806.34 GJ (FY25-26), 84,198.48 GJ (FY24-25)
  • Total: 106,206.55 GJ (FY25-26), 85,859.12 GJ (FY24-25)
  • Intensity: 8.13 GJ/₹Million turnover (FY25-26), 7.99 GJ/₹Million (FY24-25)
  • PAT Scheme: No facilities identified as Designated Consumers
  • Water Management:
  • Withdrawal: 95,462 KL (FY25-26), 77,652 KL (FY24-25)
  • Consumption: 85,515 KL (FY25-26), 73,000 KL (FY24-25)
  • Intensity: 6.55 KL/₹Million turnover (FY25-26), 6.80 KL/₹Million (FY24-25)
  • Discharge: 9,947 KL (FY25-26), 4,652 KL (FY24-25)
  • Zero Liquid Discharge: Implemented at manufacturing facilities with water reuse
  • Air Emissions: NOx - 7.40 MT, SOx - 0.41 MT, PM - 0.35 MT (FY25-26)
  • GHG Emissions:
  • Scope 1: 336.39 tCO2e (FY25-26), 263.66 tCO2e (FY24-25)
  • Scope 2: 14,648.00 tCO2e (FY25-26), 11,404.31 tCO2e (FY24-25)
  • Intensity: 1.15 tCO2e/₹Million turnover (FY25-26), 1.09 tCO2e/₹Million (FY24-25)
  • GHG Reduction Projects: LED lighting, VFDs, eco-friendly refrigerants, SF6 breaker replacement, solar installation, heat recovery
  • Waste Management:
  • Total Generated: 336.33 MT (FY25-26), 247.02 MT (FY24-25)
  • Intensity: 0.023 MT/₹Million turnover (FY25-26), 0.021 MT/₹Million (FY24-25)
  • Recycled: 319.19 MT (FY25-26), 157.33 MT (FY24-25)
  • Disposed: 17.14 MT (FY25-26), 89.71 MT (FY24-25)
  • Environmental Compliance: Fully compliant with all applicable environmental laws
Principle 7: Responsible Policy Influence
  • Trade Associations: 1 affiliation
  • Anti-competitive Conduct: No adverse orders from regulatory authorities
Principle 8: Inclusive Growth
  • Social Impact Assessments: Not applicable on CSR projects
  • Rehabilitation & Resettlement: Not applicable
  • Community Grievance: sankalp@rubicon.co.in, details at www.rubicon.co.in/csr-initiatives
  • MSME Sourcing: 5% of input material (FY25-26), 2% (FY24-25)
  • Domestic Sourcing: 45% sourced from within India (FY25-26), 43% (FY24-25)
  • Job Creation: Semi-urban - 3.31%, Urban - 46.39%, Metropolitan - 50.30% (FY25-26)
  • CSR Beneficiaries:
  • Aarambha Foundation: 35 students (100% vulnerable/marginalized)
  • Kitchen and Dining Hall: 500 students (100% vulnerable/marginalized)
  • Multipurpose Hall: Details not provided
  • Shree Santkrupa Shikshan Sanstha: 1,950 beneficiaries (100% vulnerable/marginalized)
Principle 9: Responsible Consumer Engagement
  • Consumer Complaint Mechanisms: Multiple channels including emails, toll-free number, pharmacovigilance system
  • Product Information: 100% of products carry safe and responsible usage information
  • Consumer Complaints: All categories - 0 complaints
  • Product Recalls: 0 voluntary recalls, 0 forced recalls
  • Data Breaches: 0 instances
  • Consumer Education: Through Patient Information Leaflets, product literature, packaging labels